Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Assets: 2016-2025

Historic Current Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $643.2 million.

  • Ultragenyx Pharmaceutical's Current Assets fell 19.56% to $643.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.2 million, marking a year-over-year decrease of 19.56%. This contributed to the annual value of $817.1 million for FY2024, which is 11.60% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Current Assets of $643.2 million as of Q3 2025, which was down 10.64% from $719.8 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Current Assets peaked at $1.1 billion during Q1 2021, and registered a low of $596.0 million during Q1 2024.
  • Its 3-year average for Current Assets is $730.8 million, with a median of $719.8 million in 2025.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Current Assets crashed by 40.83% in 2023 and then surged by 37.39% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Current Assets (Quarterly) stood at $856.6 million in 2021, then grew by 3.19% to $883.9 million in 2022, then dropped by 17.16% to $732.2 million in 2023, then rose by 11.60% to $817.1 million in 2024, then fell by 19.56% to $643.2 million in 2025.
  • Its last three reported values are $643.2 million in Q3 2025, $719.8 million for Q2 2025, and $699.2 million during Q1 2025.